Healthcare provider profile · identity verified

Thomas Carl Michels, MD

Family Practice · SEQUIM, WA · NPI 1891765152

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	577	171
Metoprolol Succinate	Metoprolol Succinate	332	96
Losartan Potassium	Losartan Potassium	318	88
Lisinopril	Lisinopril	311	88
Amlodipine Besylate	Amlodipine Besylate	239	72
Levothyroxine Sodium	Levothyroxine Sodium	221	62
Omeprazole	Omeprazole	165	51
Rosuvastatin Calcium	Rosuvastatin Calcium	161	56
Gabapentin	Gabapentin	156	54
Hydrochlorothiazide	Hydrochlorothiazide	156	49
Eliquis	Apixaban	139	37
Tamsulosin Hcl	Tamsulosin Hcl	139	45
Duloxetine Hcl	Duloxetine Hcl	121	38
Metformin Hcl	Metformin Hcl	121	34
Furosemide	Furosemide	114	35
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	102	17
Metformin Hcl Er	Metformin Hcl	98	31
Albuterol Sulfate Hfa	Albuterol Sulfate	96	35
Pantoprazole Sodium	Pantoprazole Sodium	86	22
Allopurinol	Allopurinol	79	21
Carvedilol	Carvedilol	75	22
Warfarin Sodium	Warfarin Sodium	64	18
Pravastatin Sodium	Pravastatin Sodium	62	18
Alendronate Sodium	Alendronate Sodium	60	20
Clopidogrel	Clopidogrel Bisulfate	57	18
Oxycodone Hcl	Oxycodone Hcl	57	21
Trazodone Hcl	Trazodone Hcl	57	20
Montelukast Sodium	Montelukast Sodium	56	15
Potassium Chloride	Potassium Chloride	56	18
Fluoxetine Hcl	Fluoxetine Hcl	55	14
Sertraline Hcl	Sertraline Hcl	52	15
Finasteride	Finasteride	48	13
Jardiance	Empagliflozin	48	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	47	11
Simvastatin	Simvastatin	44	13
Spironolactone	Spironolactone	44	18
Doxazosin Mesylate	Doxazosin Mesylate	43	11
Escitalopram Oxalate	Escitalopram Oxalate	42	11
Zolpidem Tartrate	Zolpidem Tartrate	42	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	41	15
Fluticasone Propionate	Fluticasone Propionate	39	17
Synthroid	Levothyroxine Sodium	38	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	37	suppressed
Atenolol	Atenolol	35	suppressed
Tramadol Hcl	Tramadol Hcl	35	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	34	suppressed
Ozempic	Semaglutide	34	suppressed
Chlorthalidone	Chlorthalidone	33	11
Meloxicam	Meloxicam	33	16
Paroxetine Hcl	Paroxetine Hcl	33	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	33	13
Benazepril Hcl	Benazepril Hcl	32	suppressed
Tizanidine Hcl	Tizanidine Hcl	32	18
Irbesartan	Irbesartan	30	suppressed
Xarelto	Rivaroxaban	29	suppressed
Nitroglycerin	Nitroglycerin	28	21
Prednisone	Prednisone	28	18
Quetiapine Fumarate	Quetiapine Fumarate	28	suppressed
Ipratropium Bromide	Ipratropium Bromide	27	12
Triamcinolone Acetonide	Triamcinolone Acetonide	27	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	26	suppressed
Indapamide	Indapamide	25	suppressed
Diclofenac Sodium	Diclofenac Sodium	24	12
Ezetimibe	Ezetimibe	24	suppressed
Morphine Sulfate Er	Morphine Sulfate	24	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	24	suppressed
Bupropion Xl	Bupropion Hcl	23	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	23	suppressed
Ondansetron Odt	Ondansetron	23	12
Rybelsus	Semaglutide	23	suppressed
Torsemide	Torsemide	23	suppressed
Buspirone Hcl	Buspirone Hcl	22	suppressed
Farxiga	Dapagliflozin Propanediol	22	suppressed
Lorazepam	Lorazepam	22	11
Myrbetriq	Mirabegron	22	suppressed
Citalopram Hbr	Citalopram Hydrobromide	21	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Pregabalin	Pregabalin	20	suppressed
Alprazolam	Alprazolam	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	19	suppressed
Ventolin Hfa	Albuterol Sulfate	19	suppressed
Celecoxib	Celecoxib	18	suppressed
Famotidine	Famotidine	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Primidone	Primidone	18	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Acyclovir	Acyclovir	17	11
Metoclopramide Hcl	Metoclopramide Hcl	17	suppressed
Atrovent Hfa	Ipratropium Bromide	16	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	16	suppressed
Morphine Sulfate	Morphine Sulfate	16	suppressed
Valsartan	Valsartan	16	suppressed
Clonazepam	Clonazepam	15	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	15	suppressed
Ramipril	Ramipril	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	11
Arnuity Ellipta	Fluticasone Furoate	14	suppressed
Colchicine	Colchicine	14	suppressed
Terazosin Hcl	Terazosin Hcl	14	suppressed
Testosterone Cypionate	Testosterone Cypionate	14	suppressed
Cephalexin	Cephalexin	13	suppressed
Hydrocortisone	Hydrocortisone	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Mounjaro	Tirzepatide	13	suppressed
Divalproex Sodium Er	Divalproex Sodium	12	suppressed
Glimepiride	Glimepiride	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Carvedilol Er	Carvedilol Phosphate	11	suppressed
Diltiazem 12hr Er	Diltiazem Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error